CHAPEL HILL, N.C., Feb. 27 /PRNewswire/ -- Effective communication of clinical trials can help transform an active chemical compound into a blockbuster brand. How, when, and to whom the sophisticated information of clinical trials must be delivered -- these are some of the key questions pharmaceutical companies face.
"From Breakthrough to Blockbuster: Best Practices in Communicating
Clinical Trial Results." -- A benchmarking report by Best Practices, LLC,
presents how best-in-class pharmaceutical companies communicate clinical
trial results. These findings will aid executives in making informed
budget, resource allocation, and process improvement decisions as they
prepare to release study findings.
Scope of the report
-- Choosing winning tactics for communicating study findings to
physicians, managed care organizations, investors and consumers
-- How to tailor communication, to specialist and primary care
physicians, based on their needs
-- Communication Toolkit that walks executives through the communication
process from the planning stages of a large clinical trial through the
The report is based on in-depth interviews and survey responses gathered from pharmaceutical executives at companies including Abbott, AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Schering-Plough and Wyeth.
Download a complimentary research summary including sample best practices and data charts by clicking at http://www3.best-in-class.com/rr915.htm . For more information, contact Cameron Tew at 919-767-9246 or at firstname.lastname@example.org .
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, a pharmaceutical research and consulting firm, conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class organizations. For more information, call 919-403-0251 or visit http://www.best-in-class.com .
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved